Early weight loss responders to liraglutide 3.0 mg achieved greater weight loss and regression to normoglycaemia, and reduced development of T2D at 3 years, versus early nonresponders in the SCALE obesity and prediabetes trial [abstract]
myBMI stands out for its regulation and brand-name reliability but leaves out lifestyle support and tech-based tools
The inclusion criteria for the present study included: i) Research hypotheses and methods were similar to the research content of the present article to ensure the accuracy of the narrative
Like other GLP-1 based medications, stopping treatment can lead to a return of appetite and some weight regain if no other supports are in place
Endotoxin contamination produces no visible signal in the vial
For retatrutide to be approved for clinical use, Eli Lilly must demonstrate convincing evidence of its ability to safely and effectively manage obesity in a larger, more diverse patient population